NasdaqGM - Delayed Quote USD

ArriVent BioPharma, Inc. (AVBP)

Compare
29.16 +0.17 (+0.59%)
At close: October 18 at 4:00 PM EDT
29.16 0.00 (0.00%)
After hours: October 18 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President & CEO 791.09k -- 1966
Dr. Stuart Lutzker M.D., Ph.D. Co-Founder, President of Research & Development and Director 709.43k -- 1960
Ms. Robin LaChapelle M.A. Co-Founder & COO 586.45k -- 1973
Mr. Winston Kung M.B.A. CFO & Treasurer -- -- 1976
Ms. Yang Wang Ph.D. Chief Technology Officer -- -- --
Mr. James Paul Kastenmayer J.D., Ph.D. General Counsel & Secretary -- -- 1972
Ms. Meghna Chowdary Senior Vice President of Commercial Strategy -- -- --

ArriVent BioPharma, Inc.

18 Campus Boulevard
Suite 100
Newtown Square, PA 19073
United States
628-277-4836 https://www.arrivent.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
40

Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Corporate Governance

ArriVent BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

September 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 9, 2024 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

June 5, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 25, 2024 at 12:00 AM UTC

S-1MEF: Offering Registrations

Related Tickers